WO2001030989A3 - Method for creating divergent populations of nucleic acid molecules and proteins - Google Patents

Method for creating divergent populations of nucleic acid molecules and proteins Download PDF

Info

Publication number
WO2001030989A3
WO2001030989A3 PCT/IB2000/001557 IB0001557W WO0130989A3 WO 2001030989 A3 WO2001030989 A3 WO 2001030989A3 IB 0001557 W IB0001557 W IB 0001557W WO 0130989 A3 WO0130989 A3 WO 0130989A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
acid molecules
proteins
populations
creating
Prior art date
Application number
PCT/IB2000/001557
Other languages
French (fr)
Other versions
WO2001030989A2 (en
Inventor
Wolfgang A Renner
Lars Nieba
Original Assignee
Cytos Biotechnology Ag
Wolfgang A Renner
Lars Nieba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytos Biotechnology Ag, Wolfgang A Renner, Lars Nieba filed Critical Cytos Biotechnology Ag
Priority to EP00969738A priority Critical patent/EP1226238A2/en
Priority to AU79389/00A priority patent/AU7938900A/en
Publication of WO2001030989A2 publication Critical patent/WO2001030989A2/en
Publication of WO2001030989A3 publication Critical patent/WO2001030989A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides methods for creating divergent populations of nucleic acid molecules and proteins, as well as nucleic acid molecules and proteins produced by these methods. The invention also provides processes for producing populations of antigens and antigenic determinants useful in the production of vaccines for the treatment of infectious diseases and as pharmaccine to prevent cancer.
PCT/IB2000/001557 1999-10-27 2000-10-26 Method for creating divergent populations of nucleic acid molecules and proteins WO2001030989A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP00969738A EP1226238A2 (en) 1999-10-27 2000-10-26 Method for creating divergent populations of nucleic acid molecules and proteins
AU79389/00A AU7938900A (en) 1999-10-27 2000-10-26 Method for creating divergent populations of nucleic acid molecules and proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16179699P 1999-10-27 1999-10-27
US60/161,796 1999-10-27

Publications (2)

Publication Number Publication Date
WO2001030989A2 WO2001030989A2 (en) 2001-05-03
WO2001030989A3 true WO2001030989A3 (en) 2001-11-22

Family

ID=22582767

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2000/001557 WO2001030989A2 (en) 1999-10-27 2000-10-26 Method for creating divergent populations of nucleic acid molecules and proteins

Country Status (3)

Country Link
EP (1) EP1226238A2 (en)
AU (1) AU7938900A (en)
WO (1) WO2001030989A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004110482A1 (en) * 2003-06-13 2004-12-23 Isis Innovation Limited Improved vaccines
US7303898B2 (en) * 2005-03-29 2007-12-04 New York University Defective sindbis viral vectors
WO2009043096A1 (en) * 2007-10-05 2009-04-09 Arana Therapeutics (Vic) Pty Ltd Improved method for mutagenesis
BRPI0913045A2 (en) * 2008-05-23 2017-05-23 Fit Biotech Oy alpha-virus replicase coding expression vector and use as an immune adjuvant

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018324A1 (en) * 1996-10-28 1998-05-07 The University Of Washington Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral rna
WO1998051809A1 (en) * 1997-05-12 1998-11-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors derived from hsv
WO1999050432A1 (en) * 1998-03-27 1999-10-07 Cytos Biotechnology Ag Inducible alphaviral gene expression system

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018324A1 (en) * 1996-10-28 1998-05-07 The University Of Washington Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral rna
WO1998051809A1 (en) * 1997-05-12 1998-11-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors derived from hsv
WO1999050432A1 (en) * 1998-03-27 1999-10-07 Cytos Biotechnology Ag Inducible alphaviral gene expression system

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BARTHOLOMEUSZ A ET AL: "SIGNIFICANCE OF MUTATIONS IN THE HEPATITIS B VIRUS POLYMERASE SELECTED BY NUCLEOSIDE ANALOGUES AND IMPLICATIONS FOR CONTROLLING CHRONIC DISEASE", VIRAL HEPATITIS REVIEWS,US,SAUNDERS, PHILADELPHIA, PA, vol. 4, no. 3, 1998, pages 167 - 187, XP000863517, ISSN: 1081-7050 *
FROLOV I ET AL: "ALPHAVIRUS-BASED EXPRESSION VECTORS: STRATEGIES AND APPLICATIONS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,NATIONAL ACADEMY OF SCIENCE. WASHINGTON,US, vol. 93, no. 21, 1996, pages 11371 - 11377, XP000910193, ISSN: 0027-8424 *
HAHN Y S ET AL: "MAPPING OF RNA-NEGATIVE TEMPERATURE-SENSITIVE MUTANTS OF SINDBIS VIRUS COMPLEMENTATION GROUP F MUTANTS HAVE LESIONS IN NSP4", JOURNAL OF VIROLOGY, vol. 63, no. 3, 1989, pages 1194 - 1202, XP000984665, ISSN: 0022-538X *
SCHLESINGER SONDRA ET AL: "Alphavirus vectors for gene expression and vaccines.", CURRENT OPINION IN BIOTECHNOLOGY, vol. 10, no. 5, October 1999 (1999-10-01), pages 434 - 438, XP000986381, ISSN: 0958-1669 *
TAKAHASHI M. ET AL., MOLECULAR AND CELLULAR BIOLOGY, vol. 8, January 1988 (1988-01-01), pages 347 - 352, XP000984655 *
TUBULEKAS I ET AL: "Alphavirus expression vectors and their use as recombinant vaccines: a minireview", GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES,GB,ELSEVIER SCIENCE PUBLISHERS, BARKING, vol. 190, no. 1, 29 April 1997 (1997-04-29), pages 191 - 195, XP004064401, ISSN: 0378-1119 *
WRIGHT M C AND JOYCE G F: "Continuous in vitro evolution of catalytic function", SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, no. 276, 1997, pages 614 - 617, XP002074723, ISSN: 0036-8075 *

Also Published As

Publication number Publication date
AU7938900A (en) 2001-05-08
EP1226238A2 (en) 2002-07-31
WO2001030989A2 (en) 2001-05-03

Similar Documents

Publication Publication Date Title
WO2002056905A3 (en) Molecular antigen array
WO2002034205A3 (en) Using heat shock proteins to increase immune response
NZ524888A (en) Nucleic acids and proteins from streptococcus groups A & B
WO2000075336A3 (en) Polyepitopic proteinic fragments of e6 and e7 hpv proteins, production and use thereof in vaccines
CY1110585T1 (en) PACKAGING OF CpG IMMUNIATORS WITH PARTICULAR VIRUSES: METHOD OF PREPARATION AND USE
WO2005117983A3 (en) Carrier conjugates of tnf-peptides
BR0312792A (en) Vaccine compositions containing beta1-6 amyloid antigenic series
WO2004007538A3 (en) Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
WO2004084939A3 (en) Hiv-peptide-carrier-conjugates
MX2007003171A (en) Virus-like particles comprising a fusion protein of the coat protein of ap205 and an antigenic polypeptide.
ATE441429T1 (en) GHRELIN CARRIER CONJUGATES
WO2005068639A3 (en) Particle-induced ghrelin immune response
WO2006027300A3 (en) Carrier conjugates of gnrh-peptides
CN103370413B (en) DNA expression construct
WO2003039225A3 (en) Antigen arrays comprising rankl for treatment of bone disease
WO2009080823A3 (en) Nerve growth factor conjugates and uses thereof
WO2003090687A8 (en) Using heat shock proteins to increase immune response
WO2004102198A3 (en) Selection of b cells with specificity of interest: method of preparation and use
DK1015494T3 (en) Process for the preparation of catalytic antibodies
WO2001030989A3 (en) Method for creating divergent populations of nucleic acid molecules and proteins
WO2001035989A3 (en) Use of anti-idiotypical antibodies as vaccines against cancer
NO20020615L (en) Vaccine
WO2007039458A3 (en) Hiv peptide conjugates and uses thereof
WO2003059386A3 (en) Prion protein carrier-conjugates
WO2002038611A3 (en) Method of producing antibodies by immunization with conjugates of molecules coupled to charge-modified proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000969738

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000969738

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000969738

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP